The risk of milk thistle (Silybum marianum) drug interactions
Abstract
Milk Thistle (Silybum marianum) is a widely used herbal remedy, which has a relatively low risk of drug interactions. However, there is evidence in the literature about the possible impact of thistle drugs on activity of microsomal enzymes and p-glycoprotein. Contradictory data depends on differences in study protocols. The existence in the database case reports of drug interactions with milk thistle suggests a possible clinically significant effect on the activity of cytochrome P450 enzymes.
Keywords
силибинин,
силимарин,
взаимодействия,
цитохром Р450,
silybin,
silymarin,
interactions,
cytochrome P450
About the Authors
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
K. E. Zatolochina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. Yu. Kolesnikova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
O. E. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Baeva V. M. Treatment with herbal medicines: basis of fitotherapy. — M.: Astrel; AST, 2004.
2. Lindstrom A, Ooyen C, Lynch M, Blumenthal M. (2013) Herb supplement sales increase 5.5% in 2012: herbal supplement sales rise for 9th consecutive year; turmeric sales jump 40% in natural channel. HerbalGram 99:60–65
3. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007 Jun; 6(2):110–9.
4. Alyautdin RN, Romanov BK, Gusejnov MD, Lopatin PV, Zilfikarov IN. Experimental evaluation of stressprotective activity of remedies. Russian medical journal. 2008; 3: 29–33.
5. Alyautdin RN, Guseinov MD, Zifikarov IN, Romanov BK. Stressprotective phytotherapy. Biomedicina. 2011; 1(3): 115–119.
6. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. Loguercio C, Festi D World J Gastroenterol. 2011 May 14; 17(18):2288–301.
7. Blaising J, Lévy PL, Gondeau C, Phelip C, Varbanov M, Teissier E, Ruggiero F, Polyak SJ, Oberlies NH, Ivanovic T, Boulant S, Pécheur EI. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol. 2013 Nov; 15(11): 1866–82. doi: 10.1111/cmi.12155.
8. Gufford BT, Chen G, Vergara AG, Lazarus P, Oberlies NH, Paine MF. Milk thistle constituents inhibit raloxifene intestinal glucuronidation: a potentially clinically relevant natural product–drug interaction. Drug Metab Dispos. 2015; 43(9): 1353–1359. doi: 10.1124/dmd.115.065086.
9. Kawaguchi-Suzuki M, Frye RF, Zhu HJ, et al. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos. 2014; 42(10): 1611– 1616. doi: 10.1124/dmd.114.057232.
10. Wu J-W, Lin L-C, Tsai T-H. Drug–drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol. 2009; 121(2): 185–193. doi: 10.1016/j.jep. 2008.10.036.
11. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH, Beckurts KT, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol. 2000 Jun; 86(6): 250–6.
12. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos. 2000 Nov; 28(11): 1270–3.
13. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004 Jun; 32(6): 587–94.
14. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung. 2004; 54(2): 109–13.
15. Han Y, Guo D, Chen Y, Chen Y, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol. 2009 Jun; 65(6): 585–91.
16. Han YU, Guo D, Chen Y, et al. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica. 2009; 39: 694–699.
17. Gurley BJ, Barone GW,Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. S Drug Metab Dispos. 2006 Jan; 34(1): 69–74.
18. Deng JW, Shon JH, Shin HJ, et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharmaceutical Research. 2008; 25: 1807– 1814.
19. Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Monitoring of drug safety. Safety and risk of pharmacotherapy. 2014; 3(4): 11–14.
Review
For citations:
Kazakov A.S., Zatolochina K.E., Kolesnikova E.Yu., Zhuravleva O.E. The risk of milk thistle (Silybum marianum) drug interactions. Safety and Risk of Pharmacotherapy. 2016;(1):33-37. (In Russ.)
Views:
1649
Email this article 